Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Repare Therapeutics Receives $1.5M Ono Research Payment | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Repare Therapeutics Receives $1.5M Ono Research Payment

Achieves a specified research trigger under Repare's small molecule Polθ inhibitor program.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Repare Therapeutics Inc., a clinical-stage precision oncology company, has received an approximately $1.5 million research service payment from Ono Pharmaceutical Company, Ltd. for the achievement of a specified research trigger, under the companies’ 2019 strategic partnership. Under the agreement, Repare is primarily responsible for carrying out research activities for its Polθ program, now known as RP-2119, until the first submission of an IND in the U.S. or Japan. 
 
“This reflects an important milestone in our RP-2119 Polθ program, as we undertake our IND-enabling studies and prepare for our previously guided initiation of clinical trials in the summer of 2023,” said Kim A. Seth, Chief Business Officer of Repare.
 
In January 2019, Repare entered into an exclusive strategic research, development and commercialization partnership with Ono for Repare’s small molecule Polθ inhibitor program in Japan, South Korea, Taiwan, Hong Kong, Macau and ASEAN countries, excluding mainland China. Repare retains rights to develop and commercialize the products outside the ONO territory, including the U.S., Canada and EU. Ono paid Repare approximately $8.1 million, comprised of an initial upfront fee and research service payments. In October 2021, upon the occurrence of a specified research trigger, Repare became eligible to receive a portion, amounting to ¥100 million ($0.9 million), of the research service payments.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics